{"id":"adalimumab-plus-prednisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immunosuppression-related complications"},{"rate":null,"effect":"Corticosteroid-related effects (weight gain, hyperglycemia, osteoporosis)"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a monoclonal antibody that binds TNF-α and prevents its interaction with TNF receptors, thereby suppressing inflammatory cytokine signaling. Prednisone is a corticosteroid that broadly suppresses immune cell activation and inflammatory mediator production. Together, this combination provides dual anti-inflammatory and immunosuppressive effects for managing severe inflammatory or autoimmune conditions.","oneSentence":"Adalimumab blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation, while prednisone provides additional immunosuppression via glucocorticoid receptor activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:22.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease, ulcerative colitis)"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Other TNF-α-responsive autoimmune or inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT02619552","phase":"","title":"Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-08","conditions":"Crohn's Disease, IBD","enrollment":50},{"nctId":"NCT05120687","phase":"","title":"Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-10-15","conditions":"Vogt Koyanagi Harada Disease (VKH)","enrollment":200},{"nctId":"NCT05105347","phase":"PHASE4","title":"Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-11-10","conditions":"Uveitis","enrollment":130},{"nctId":"NCT01124838","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":261},{"nctId":"NCT01138657","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":239},{"nctId":"NCT01235689","phase":"PHASE3","title":"Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02-11","conditions":"Crohn's Disease","enrollment":252},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT00480272","phase":"PHASE4","title":"Prospective Study on Intensive Early Rheumatoid Arthritis Treatment","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2007-05","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02878161","phase":"PHASE4","title":"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From \"Real World\"","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2016-01","conditions":"Rheumatoid Arthritis","enrollment":240},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["humira (adalimumab)","deltacortene (prednisone)"],"phase":"marketed","status":"active","brandName":"adalimumab, plus prednisone","genericName":"adalimumab, plus prednisone","companyName":"Fondazione IRCCS Policlinico San Matteo di Pavia","companyId":"fondazione-irccs-policlinico-san-matteo-di-pavia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation, while prednisone provides additional immunosuppression via glucocorticoid receptor activation. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease, ulcerative colitis), Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}